pillbase.ru

Fasenra

Active substance: benralizumab

Benralizumab

Centralised EU authorisationActive

Marketing holder: AstraZeneca AB

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 4
  • Benralizumab
    INJECTION, SOLUTION · BENRALIZUMAB 10 mg/.5mL
    61434-066
    Catalent Indiana, LLC
  • FASENRA
    INJECTION, SOLUTION · BENRALIZUMAB 10 mg/.5mL
    0310-1745
    AstraZeneca Pharmaceuticals LP
  • FASENRA
    INJECTION, SOLUTION · BENRALIZUMAB 30 mg/mL
    0310-1730
    AstraZeneca Pharmaceuticals LP
  • FASENRA
    INJECTION, SOLUTION · BENRALIZUMAB 30 mg/mL
    0310-1830
    AstraZeneca Pharmaceuticals LP
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-9502-7d85-8a3e-cd216986eb95,01a1208d-7179-7969-a099-c3157b97e64a,01a1208f-8223-78eb-a52b-03316756d1fa,01a12092-4328-7970-94e1-32119742acdb;count=4 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/004433
Registration status
Active
ATC code
R03DX10
Sources
  • product · EMA · EMEA/H/C/004433 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/004433 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/004433 · Verified 2026-10-09